PharmAust Limited

PAA

AU000000PAA1

Pharmaceuticals

Market Closed - Australian S.E. Other stock markets 07:10:19 24/05/2024 BST			5-day change	1st Jan Change
0.18 ^AUD	0.00%		-2.70%	+56.52%

05-17	PharmAust Appoints Nonexecutive Chair; Shares Up 3%	MT
05-17	PharmAust Obtains Orphan Drug Designation for Monepantel; Shares Up 5%	MT

PharmAust Appoints Barbara Kitchell to Veterinary Advisory Board

December 17, 2017 at 11:34 pm

PharmAust appointed Dr. Barbara Kitchell to its Veterinary Advisory Board. Dr. Kitchell is Director of Residency Training for Veterinary Centers of America and staff oncologist at the VCA Veterinary Care Animal Hospital and Referral Center in New Mexico. Previously, she was Professor and Director of the Center for Comparative Oncology at Michigan State University.

Latest news about PharmAust Limited

PharmAust Appoints Nonexecutive Chair; Shares Up 3%	05-17	MT
PharmAust Obtains Orphan Drug Designation for Monepantel; Shares Up 5%	05-17	MT
Pharmaust Appoints Interim Chair, Managing Director; Shares Fall 16%	05-09	MT
Pharmaust CEO Resigns	04-23	MT
PharmAust Obtains Approval to Commence Monepantel Extension Study	04-10	MT
PharmAust Retracts CEO Statement from Media	04-02	MT
PharmAust Submits Supporting Data to US FDA for Monepantel Orphan Drug Designation Request; Shares Down 7%	03-14	MT
PharmAust Limited Reports Earnings Results for the Half Year Ended December 31, 2023	02-29	CI
PharmAust Gets US FDA Guidance for Motor Neuron Disease Medication	02-16	MT
PharmAust Appoints Non-Executive Director	02-07	MT
PharmAust Secures Ethics Approval for Phase One Motor Neuron Disease Extension Study; Shares Rise 6%	01-30	MT
PharmAust to Amend Monepantel Orphan Drug Designation Request to FDA	01-28	MT
PharmAust Ties Up with Berry Consultants for Upcoming Phase 2/3 Motor Neuron Disease Trial; Shares Rise 4%	01-16	MT
PharmAust Secures Meeting with US FDA for Motor Neuron Disease Drug Application; Shares Jump 9%	01-02	MT
PharmAust Secures Support for Phase 2/3 Clinical Trial Grant Request	12-26	MT
PharmAust Secures R&D Tax Refund for Fiscal Year 2023	12-20	MT
PharmAust Achieves 93% take Up on Options Offer	12-15	MT
PharmAust to Raise AU$3.5 Million From Share Sale	12-14	MT
PharmAust Concludes Phase One Study for Motor Neuron Disease Medication	12-01	MT
Pharmaust Completes Dosing for All Cohort Four Patients in Phase One Study of Motor Neurone Disease; Shares Rise 3%	13/10/23	MT
PharmAust Limited Reports Earnings Results for the Full Year Ended June 30, 2023	31/08/23	CI
PharmAust Limited Appoints Roger Aston as Non-Executive Chairman, Effective 1 September 2023	28/08/23	CI
PharmAust Limited Announces Executive Changes	28/08/23	CI
PharmAust Concludes Pharmacokinetics Study in Third Group of MND Patients	09/08/23	MT
PharmAust Subsidiary Enters Voluntary Liquidation	01/08/23	MT

Chart PharmAust Limited

Duration

Period

More charts

Company Profile

PharmAust Limited is a clinical-stage biotechnology company developing therapeutics for human and animal health applications. The Companyâs segments include Corporate and Research. The Company is focused on repurposing monepantel (MPL) for human neurodegenerative diseases. The Company's lead candidate, Monepantel (MPL), is a potent and safe inhibitor of the mTOR pathway, that plays a central role in cell growth and proliferation of cancer cells and in degenerating neurons. The Company is also developing MPL as a treatment for motor neuron disease (MND/ALS), a rare, incurable disease. It is focused on starting Phase II/III clinical study of MPL. It has also completed a Phase II oncology clinical study of MPL in humans and pilot studies in canine cancer. It is also preparing a pivotal monepantel field trial in dogs with B-Cell Lymphoma to enable product registration in the United States.

Sector

Pharmaceuticals

Calendar

29/08/2024 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
PHARMAUST LIMITED	+56.52%	47.25M
ELI LILLY AND COMPANY	+38.51%	727B
NOVO NORDISK A/S	+33.05%	599B
JOHNSON & JOHNSON	-6.23%	354B
MERCK & CO., INC.	+18.78%	328B
ABBVIE INC.	+1.35%	277B
ASTRAZENECA PLC	+16.00%	243B
NOVARTIS AG	+8.09%	205B
ROCHE HOLDING AG	-5.77%	203B
AMGEN INC.	+6.19%	164B